Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Luoxin Pharmaceuticals Group Stock Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥3.58 |
52 Week High | CN¥6.28 |
52 Week Low | CN¥3.22 |
Beta | 0.52 |
11 Month Change | -27.24% |
3 Month Change | -22.17% |
1 Year Change | -33.58% |
33 Year Change | -63.02% |
5 Year Change | n/a |
Change since IPO | -71.36% |
Recent News & Updates
Recent updates
Shareholder Returns
002793 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -6.3% | -2.6% | -2.7% |
1Y | -33.6% | -15.9% | -17.4% |
Return vs Industry: 002793 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 002793 underperformed the CN Market which returned -17.4% over the past year.
Price Volatility
002793 volatility | |
---|---|
002793 Average Weekly Movement | 6.7% |
Pharmaceuticals Industry Average Movement | 5.6% |
Market Average Movement | 6.7% |
10% most volatile stocks in CN Market | 10.1% |
10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 002793's share price has been volatile over the past 3 months.
Volatility Over Time: 002793's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 3,388 | Baoqi Liu | www.luoxin.cn |
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Fundamentals Summary
002793 fundamental statistics | |
---|---|
Market cap | CN¥3.89b |
Earnings (TTM) | -CN¥607.56m |
Revenue (TTM) | CN¥2.39b |
1.6x
P/S Ratio-6.4x
P/E RatioIs 002793 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
002793 income statement (TTM) | |
---|---|
Revenue | CN¥2.39b |
Cost of Revenue | CN¥1.42b |
Gross Profit | CN¥969.23m |
Other Expenses | CN¥1.58b |
Earnings | -CN¥607.56m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.56 |
Gross Margin | 40.55% |
Net Profit Margin | -25.42% |
Debt/Equity Ratio | 70.2% |
How did 002793 perform over the long term?
See historical performance and comparison